Savara Inc

SVRA ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Revenue $257.0K $0
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development
SG&A Expense $42.1M $25.0M $15.7M $10.9M $12.4M $14.3M $13.1M
Operating Income $-123.5M $-103.2M $-60.0M $-38.8M $-41.5M $-49.3M $-79.0M
Operating Margin -19,182.9%
Interest Expense
Pretax Income $-118.8M $-95.9M $-54.7M $-38.2M $-43.0M $-49.6M $-78.2M
Income Tax Expense $0 $9.0K
Net Income $-118.8M $-95.9M $-54.7M $-38.2M $-43.0M $-49.6M $-78.2M
Net Margin -19,305.4%
EPS (Basic) $-0.53 $-0.48 $-0.33 $-0.25 $-0.32 $-0.84 $-1.95
EPS (Diluted) $-0.53 $-0.48 $-0.33 $-0.25 $-0.32 $-0.84 $-1.95
Shares Outstanding (Basic) 204.7M 222.4M 198.2M 165.2M 152.8M 133.9M 54.2M 50.8M
Shares Outstanding (Diluted) 204.7M 222.4M 198.2M 165.2M 152.8M 133.9M 54.2M 50.8M
Dividends Per Share
← Newer Page 1 of 4 Older →